STXS - Fluidigm COVID-19 Funding And Other News: The Good Bad And Ugly Of Biopharma
Fluidigm receives NIH funding for COVID-19 testing technology
Fluidigm Corporation (FLDM) announced that it has inked a letter contract with the National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering. The contract pertains to a probable project under the Rapid Acceleration of Diagnostics (RADx) program. The project has proposed budget of up to $37 million and intends to expand production capacity for COVID-19 testing using Fluidigm microfluidics technology.
The main aim of the RADx program is to facilitate deployment of nearly 6 million daily tests nationwide by December 2020. The project